RAREUltragenyx Pharmaceutical Inc.

RARE Stock Price, Valuation & Chart | Ultragenyx Pharmaceutical Inc.

Compare

$26.530+0.72 (+2.79%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology RARE intrinsic value RARE calculated fair value vs price

Overview Financials Dividends Ratios

RARE Historical price chart

RARE Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.61B

PE Ratio-4.54

EPS-5.84

Trading Volume5.82M

Today's High/Low26.8/25.57

Dividend Yield0.00

52 Week High/Low39.89/18.29

Shares Outstanding98.49M

RARE Financial Statement

RARE Analyst ratings

RARE Analysis & performance metrics

RARE Company profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the…

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of…

RARE Management team

Name

Position

Eric Crombez M.D.

Chief Medical Officer & Executive Vice President

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

Karah Herdman Parschauer J.D.

Chief Legal Officer & Executive Vice President of Corporate Affairs

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

Thomas R. Kassberg

Chief Business Officer & Executive Vice President

Emil D. Kakkis M.D., Ph.D.CEO

Founder, President, Chief Executive Officer & Director

Erik Harris M.B.A.

Executive Vice President & Chief Commercial Officer

Howard HornCFO

Executive Vice President of Corporate Strategy & Chief Financial Officer

Name

Position

Eric Crombez M.D.

Chief Medical Officer & Executive Vice President

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

Karah Herdman Parschauer J.D.

Chief Legal Officer & Executive Vice President of Corporate Affairs

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

Thomas R. Kassberg

Chief Business Officer & Executive Vice President

Emil D. Kakkis M.D., Ph.D.CEO

Founder, President, Chief Executive Officer & Director

Erik Harris M.B.A.

Executive Vice President & Chief Commercial Officer

Howard HornCFO

Executive Vice President of Corporate Strategy & Chief Financial Officer

Management Team

Eric Crombez M.D.

Chief Medical Officer & Executive Vice President

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

Karah Herdman Parschauer J.D.

Chief Legal Officer & Executive Vice President of Corporate Affairs

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

Thomas R. Kassberg

Chief Business Officer & Executive Vice President

Emil D. Kakkis M.D., Ph.D.CEO

Founder, President, Chief Executive Officer & Director

Erik Harris M.B.A.

Executive Vice President & Chief Commercial Officer

Howard HornCFO

Executive Vice President of Corporate Strategy & Chief Financial Officer

Management

Eric Crombez M.D.

Chief Medical Officer & Executive Vice President

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

Karah Herdman Parschauer J.D.

Chief Legal Officer & Executive Vice President of Corporate Affairs

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

Thomas R. Kassberg

Chief Business Officer & Executive Vice President

Emil D. Kakkis M.D., Ph.D.CEO

Founder, President, Chief Executive Officer & Director

Erik Harris M.B.A.

Executive Vice President & Chief Commercial Officer

Howard HornCFO

Executive Vice President of Corporate Strategy & Chief Financial Officer

Total 8 executives

RARE Frequently asked questions

What is Ultragenyx Pharmaceutical Inc. (RARE) Stock Price?

Current stock price of Ultragenyx Pharmaceutical Inc. (RARE) stock is $26.530. The stock price is +2.79% higher in the session. The intraday range can be seen from this page. Volume of Ultragenyx Pharmaceutical Inc. (RARE) stock is 5.82M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Ultragenyx Pharmaceutical Inc. (RARE) stock price going up or down today?

The stock price of Ultragenyx Pharmaceutical Inc. (RARE) can change with earnings, company news, and overall market sentiment. Ultragenyx Pharmaceutical Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Ultragenyx Pharmaceutical Inc. stock expensive at its current price?

Whether Ultragenyx Pharmaceutical Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for RARE on this page is -4.54. EPS on this page is -5.84. Compare those figures with peers and growth expectations before deciding if the current Ultragenyx Pharmaceutical Inc. price is justified.

How has the stock price of Ultragenyx Pharmaceutical Inc. (RARE) performed historically?

Historical performance for Ultragenyx Pharmaceutical Inc. (RARE) is shown on the price chart on this page. Review multi-period moves alongside volume to see how RARE reacted to past earnings and market events.

Should I buy Ultragenyx Pharmaceutical Inc. (RARE) stock, at this price?

Buying Ultragenyx Pharmaceutical Inc. (RARE) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.